A Phase 3, Multinational, Randomized, Open-label, Parallel-arm Study Of Avelumab (msb0010718c) In Combination With Axitinib (Inlyta(Registered)) Versus Sunitinib (Sutent(Registered)) Monotherapy In The First-line Treatment Of Patients With Advanced Renal Cell Carcinoma
Phase of Trial: Phase III
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Avelumab (Primary) ; Axitinib; Sunitinib
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms JAVELIN Renal 101
- Sponsors Pfizer
- 29 Dec 2017 Planned primary completion date changed from 1 Dec 2018 to 2 Dec 2018.
- 21 Dec 2017 According to a Pfizer media release, the company anticipates completing this trial at the end of 2018.
- 19 Sep 2017 Planned End Date changed from 1 Sep 2020 to 30 Apr 2021.